

Patent
Attorney Docket: 892,280-210
(Formerly 342312004300)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims

1-56. (Canceled)

57. (Currently Amended) A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by five to ten days and wherein the amount of the initial dose is about 200 mg to about 1500 mg ~~1000 mg~~ and the amount of each subsequent dose is about 200 mg to about 1500 mg ~~500 mg~~.

58. (Previously Presented) The method of claim 57, the method comprising administering a single subsequent dose.

59. (Previously Presented) The method of claim 58, wherein the subsequent dose is administered approximately one week after the initial dose without any intervening dose of dalbavancin.

60. (Previously Presented) The method of claim 57, the method comprising administering multiple subsequent doses.

Patent
Attorney Docket: 892,280-210
(Formerly 342312004300)

61. (Previously Presented) The method of claim 60, wherein said subsequent doses are administered at approximately one week intervals without any intervening doses of dalbavancin.

62. (New) The method of claim 57, wherein the bacterial infection is a skin and soft tissue infection.

63. (New) The method of claim 57, wherein the amount of the initial dose is about 1500 mg.

64. (New) The method of claim 57, wherein the amount of the initial dose is about 1000 mg.

65. (New) The method of claim 57, wherein the amount of the initial dose is about 800 mg.

66. (New) The method of claim 57, wherein the amount of the initial dose is about 500 mg.

67. (New) The method of claim 57, wherein the amount of each subsequent dose is about 400 mg to about 1000 mg.

68. (New) The method of claim 57, wherein the amount of each subsequent dose is about 500 mg.

69. (New) The method of claim 57, wherein the amount of each subsequent dose is about 400 mg.

Patent
Attorney Docket: 892,280-210
(Formerly 342312004300)

70. (New) The method of claim 57, wherein the amount of each subsequent dose is about 250 mg.

71. (New) The method of claim 57, wherein the amount of each subsequent dose is about 200 mg.

72. (New) The method of claim 57, wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 250 mg.

73. (New) A method for treating a bacterial infection in a human in need thereof, the method comprising:

administering initial and subsequent therapeutically effective doses of dalbavancin in a pharmaceutically acceptable carrier to the patient,

wherein each dose is separated by approximately one week and wherein the amount of the initial dose is about 1000 mg and the amount of each subsequent dose is about 500 mg.

74. (New) The method of claim 73, the method comprising administering a single subsequent dose.

75. (New) The method of claim 73, wherein the subsequent dose is administered approximately one week after the initial dose without any intervening dose of dalbavancin.

76. (New) The method of claim 73, the method comprising administering multiple subsequent doses.

Patent
Attorney Docket: 892,280-210
(Formerly 342312004300)

77. (New) The method of claim 76, wherein said subsequent doses are administered at approximately one week intervals without any intervening doses of dalbavancin.

78. (New) The method of claim 73, wherein the bacterial infection is a skin and soft tissue infection.